Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.

According to Zacks, “Conatus presently has no approved product in its portfolio. However, its progress with the lead candidate, emricasan has been encouraging. Emricasan is in phase II development for the treatment of chronic liver disease, including NASH fibrosis. Conatus also plans to initiate studies on emricasan targeting different types of NASH patient populations. Moreover, the stock has outperformed the industry in the last one year. On the flip side, though emricasan is progressing well, it is still several years away from entering the market, if at all. Any development/regulatory setback could hamper Conatus’ prospects. Notably, several companies are working on developing treatments for NASH which might make the market competitive for emricasan. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has positive record of earnings surprises in recent quarters.”

A number of other analysts have also recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Conatus Pharmaceuticals in a research note on Thursday, June 29th. ValuEngine upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 24th. Finally, Aegis reiterated a “buy” rating and issued a $11.00 target price on shares of Conatus Pharmaceuticals in a research note on Monday, May 15th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Conatus Pharmaceuticals presently has an average rating of “Buy” and an average price target of $13.25.

Conatus Pharmaceuticals (CNAT) traded up 2.3725% on Monday, reaching $6.1833. 201,861 shares of the company were exchanged. The stock’s market capitalization is $161.81 million. The stock has a 50-day moving average price of $5.64 and a 200 day moving average price of $5.55. Conatus Pharmaceuticals has a 52 week low of $1.45 and a 52 week high of $9.40.

Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.20. The company had revenue of $7 million for the quarter, compared to analyst estimates of $5.88 million. During the same quarter in the prior year, the business posted ($0.35) earnings per share. Analysts forecast that Conatus Pharmaceuticals will post ($0.71) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Conatus Pharmaceuticals Inc. (CNAT) Upgraded to Hold at Zacks Investment Research” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/24/conatus-pharmaceuticals-inc-cnat-upgraded-to-hold-at-zacks-investment-research.html.

Hedge funds have recently bought and sold shares of the stock. Bank of Montreal Can acquired a new stake in Conatus Pharmaceuticals during the second quarter worth about $109,000. Courage Capital Management LLC raised its position in Conatus Pharmaceuticals by 25.0% in the first quarter. Courage Capital Management LLC now owns 125,000 shares of the biotechnology company’s stock worth $721,000 after buying an additional 25,000 shares in the last quarter. Renaissance Technologies LLC raised its position in Conatus Pharmaceuticals by 28.1% in the first quarter. Renaissance Technologies LLC now owns 235,290 shares of the biotechnology company’s stock worth $1,358,000 after buying an additional 51,590 shares in the last quarter. Bank of New York Mellon Corp raised its position in Conatus Pharmaceuticals by 2.1% in the first quarter. Bank of New York Mellon Corp now owns 80,310 shares of the biotechnology company’s stock worth $464,000 after buying an additional 1,655 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new position in Conatus Pharmaceuticals during the first quarter worth approximately $854,000. Hedge funds and other institutional investors own 18.68% of the company’s stock.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Get a free copy of the Zacks research report on Conatus Pharmaceuticals (CNAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.